{"entity":{"id":"jabez-biosciences","kind":"company","name":"Jabez Biosciences","aka":["Jabez Bioscience"],"tldr":"Jabez Biosciences makes JBZ-001, a tablet that blocks an enzyme cancer cells need to build new DNA and RNA building blocks. It is in a first trial in people with advanced solid tumours and non-Hodgkin lymphoma.","summary":"Jabez Biosciences, Inc., with releases datelined Zionsville, Indiana, describes itself as a lean drug development company that licenses academic discoveries into cancer therapies it calls '3-S' (seamless, scalable, synergistic). Its lead compound JBZ-001 is an oral inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme of pyrimidine synthesis. A first-in-human phase 1 dose-escalation and expansion trial (NCT06801002) in refractory solid tumours and non-Hodgkin lymphoma dosed its first patient at The Ohio State University Comprehensive Cancer Center in April 2025, added a second site in August 2025, and first-in-human pharmacokinetic and pharmacodynamic data were presented at AACR 2026. The company is raising money from the public through a Regulation A+ offering. Its first registered cancer trial, NCT06801002, was posted on ClinicalTrials.gov in January 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.jabezbio.com/"},{"label":"First patient dosed, April 2025","url":"https://www.jabezbio.com/2025/04/03/jabez-biosciences-inc-announces-first-patient-dosed-in-phase-1-oncology-clinical-study-of-jbz-001/"},{"label":"ClinicalTrials.gov: phase 1 trial of JBZ-001 (NCT06801002)","url":"https://clinicaltrials.gov/study/NCT06801002"}],"tags":[],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":["targeted-therapy"],"technologies":["metabolic-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the pages read on 29 October 2026.","The company's website is written largely as an investment solicitation; its claims about efficacy and market size are not repeated here.","DHODH inhibition is filed under the metabolic therapy technology record because it starves cancer cells of pyrimidine nucleotides; there is no dedicated record.","No financing round with an amount was read."],"hq":"Zionsville, IN","country":"US","companyType":"biotech","website":"https://www.jabezbio.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/jabez-biosciences/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"metabolic-therapy","kind":"technology","name":"Metabolic therapy: starving the tumour of a nutrient","route":"/technologies/metabolic-therapy/"}]}}